TABLE 2.

Change in lung function parameters from baseline to week 52 in patients with and without PAO

	Tezepelumab 210 mg Q4W			Placebo			LS mean difference (95% CI)
	Baseline, mean±sd	n	LS mean±se change from baseline	Baseline, mean±sd	n	LS mean±se change from baseline
Patients with PAO
Pre-bronchodilator FVC L	2.84±0.90	385	0.25±0.02	2.91±0.96	393	0.08±0.02	0.17 (0.10–0.23)
Post-bronchodilator FVC L	3.13±0.96	356	0.13±0.02	3.20±1.01	348	0.00±0.02	0.13 (0.07–0.19)
Post-bronchodilator FEV1 L	1.79±0.61	356	0.18±0.02	1.84±0.63	348	0.02±0.02	0.15 (0.10–0.21)
Post-bronchodilator FEV1/FVC %	57.48±9.28	356	2.09±0.40	57.50±8.91	348	−0.38±0.40	2.47 (1.51–3.43)
Post-bronchodilator FEV1 reversibility %	17.00±16.00	352	−5.68±0.62	17.11±16.54	344	−3.33±0.63	−2.35 (−4.08–−0.62)
Patients without PAO
Pre-bronchodilator FVC L	3.01±0.94	274	0.20±0.03	3.01±0.85	274	0.11±0.03	0.09 (0.01–0.17)
Post-bronchodilator FVC L	3.21±0.96	245	0.10±0.03	3.22±0.85	242	0.02±0.03	0.08 (0.01–0.15)
Post-bronchodilator FEV1 L	2.53±0.77	245	0.07±0.03	2.54±0.71	242	−0.01±0.03	0.08 (0.01–0.14)
Post-bronchodilator FEV1/FVC %	79.07±6.66	245	0.91±0.51	78.74±6.85	242	0.67±0.51	0.24 (−0.92–1.39)
Post-bronchodilator FEV1 reversibility %	15.14±17.12	243	−7.62±0.75	15.87±16.11	240	−6.66±0.75	−0.97 (−3.04–1.11)

PAO: persistent airflow obstruction; Q4W: every 4 weeks; LS: least-squares; FVC: forced vital capacity; FEV₁: forced expiratory volume in 1 s.